Eleven Biotherapeutics (EBIO) Misses Q4 EPS by 13c

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q4 EPS of ($0.49), $0.13 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $375 million versus the consensus estimate of $800 thousand.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Meritage Homes Corporation (MTH) Tops Q1 EPS by 151c; offers guidance
• SLM (SLM) Tops Q1 EPS by 20c; offers guidance
• FS Bancorp (FSBW) Tops Q1 EPS by 8c